Switch to Bupropion or Mirtazapine for SSRI-Intolerant Depression
For a patient experiencing persistent vomiting with multiple SSRIs (fluoxetine, citalopram, escitalopram) and no response to buspirone, switch to either bupropion or mirtazapine as first-line alternatives, with bupropion preferred if sexual side effects are a concern and mirtazapine preferred if appetite stimulation and sedation would be beneficial. 1
Why SSRIs Are Causing Vomiting
- Nausea and vomiting are the most common adverse effects of SSRIs and represent the leading cause of treatment discontinuation in clinical trials 1, 2
- All three SSRIs this patient tried (fluoxetine, citalopram, escitalopram) have high rates of gastrointestinal side effects, with escitalopram and sertraline being among the least tolerated on the gastrointestinal tract 3
- The mechanism involves excessive serotonin stimulation of 5-HT3 receptors in the gut, which triggers the vomiting reflex 3
Recommended Alternative: Bupropion
Bupropion is the optimal first choice because it works through dopamine and norepinephrine mechanisms rather than serotonin, avoiding the gastrointestinal side effects that plagued this patient's SSRI trials. 1
- Bupropion has significantly lower rates of nausea and vomiting compared to SSRIs because it does not affect serotonin reuptake 1
- Bupropion is associated with the lowest rate of sexual adverse events among second-generation antidepressants, which is an additional benefit over SSRIs 1
- The American College of Physicians recommends selecting antidepressants based on adverse effect profiles when efficacy is equivalent across agents 1
Alternative Option: Mirtazapine
Mirtazapine is the second-best choice and may actually be superior if the patient has weight loss or insomnia, as it has the fewest gastrointestinal side effects of all antidepressants. 3
- Mirtazapine was shown to be the antidepressant with the fewest side effects on the gut, being associated only with increased appetite rather than nausea or vomiting 3
- Mirtazapine has a faster onset of action than fluoxetine, paroxetine, or sertraline, potentially providing quicker symptom relief 1
- The sedating and appetite-stimulating properties can be therapeutic if the patient has insomnia or poor appetite from depression 3
Clinical Implementation
- Start bupropion at 150 mg once daily for 3 days, then increase to 150 mg twice daily (or use extended-release formulation at 150 mg daily, increasing to 300 mg daily after one week) 1
- If choosing mirtazapine instead, start at 15 mg at bedtime and increase to 30-45 mg as needed for response 1
- Monitor patient status, therapeutic response, and adverse effects within 1-2 weeks of initiation, as recommended for all antidepressant therapy 1
Critical Monitoring Points
- Close monitoring for suicidal thoughts and behaviors is essential during the first 1-2 months of any antidepressant treatment, as SSRIs and other second-generation antidepressants increase the risk of nonfatal suicide attempts 1, 2
- Watch for emergence of agitation, irritability, or unusual behavioral changes that may indicate worsening depression 1
- If the patient does not achieve adequate response after 6-12 weeks at therapeutic doses, consider switching to the alternative medication (mirtazapine if started on bupropion, or vice versa) 1
Why Not Other Options
- Duloxetine (an SNRI) also has significant gastrointestinal side effects and would likely cause similar vomiting problems 4, 3
- Venlafaxine (another SNRI) similarly affects serotonin and has high rates of nausea 3
- Tricyclic antidepressants have even worse side effect profiles and are not recommended as first-line agents 1
- Buspirone already failed in this patient and is primarily an anxiolytic rather than a primary antidepressant 1